We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 14, 2020

Concordance Between CA-125 and RECIST Progression in Patients With BRCA-Mutated Relapsed Ovarian Cancer

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Concordance Between CA-125 and RECIST Progression in Patients With Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer Treated in the SOLO2 Trial With Olaparib as Maintenance Therapy After Response to Chemotherapy
Eur. J. Cancer 2020 Nov 01;139(xx)59-67, A Tjokrowidjaja, CK Lee, M Friedlander, V Gebski, L Gladieff, J Ledermann, R Penson, A Oza, J Korach, T Huzarski, L Manso, C Pisano, R Asher, SJ Lord, SI Kim, JY Lee, N Colombo, TW Park-Simon, K Fujiwara, G Sonke, I Vergote, JW Kim, E Pujade-Lauraine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading